The aims of this study were: (i) to provide relevant equations to estimate TRL-C from non-fasting lipids, regardless apoB100 availability; (ii) to establish the performance and equivalence of TG-based markers vs. TRL-C and TRL-C/apoA-I, a continuous estimator of atherogenic dyslipidemia (AD); and (iii) to derive an unbiased equation predicting TRL-C from non-fasting TG. Here, APOB is linked to Alzheimer disease.